Validation of a minimal panel of antibodies for the diagnosis of malignant pleural mesothelioma

Pathology

Volumn 43, Issue 4, 2011, Pages 313-317

  Kao, Steven Chuan Hao ^a,b   Griggs, Kim ^g   Lee, Kenneth ^c   Armstrong, Nicola ^d   Clarke, Stephen ^a,b   Vardy, Janette ^b   Van Zandwijk, Nico ^a   Burn, Juliet ^e   McCaughan, Brian C ^f   Henderson, Douglas W ^h   Klebe, Sonja ^h  

^a Bernie Banton Centre   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Department of Microbiology and Infectious Diseases   (Australia)

^d GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^e Davies Campbell de Lambert Pathology   (Australia)

^f ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^g FLINDERS UNIVERSITY   (Australia)

^h FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

Antibody; Calretinin; D2 40; Malignant pleural mesothelioma

Indexed keywords

EID: 80052218671     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e32834642da     Document Type: Article

References (15)

1. Kazan-Allen L. Killing the Future - Asbestos Use in Asia. London: IBAS, 2007.
2. Henderson D, Shilkin K, Langlois S, et al. Malignant Mesothelioma. New York: Hemisphere, 1992.
3. Husain A, Colby T, Ordonez N, et al. Guidelines for pathologic diagnosis of malignant mesothelioma. A consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2009; 133: 1317-31.
4. Muller A, Franke F, Muller D. D2-40: a reliable marker in the diagnosis of pleural mesothelioma. Pathobiology 2006; 73: 50-4. (Pubitemid 43952605)
5. Hinterberger M, Reineke T, Storz M, et al. D2-40 and calretinin - a tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiation. Mod Pathol 2007; 20: 245-55.
6. Chu A, Litzky L, Pasha T, et al. Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol 2005; 18: 105-10. (Pubitemid 40128102)
7. Ordóñez NG. D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum Pathol 2005; 36: 372-80. (Pubitemid 40591807)
8. King J, Thatcher N, Pickering C, et al. Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systemic analysis using published data. Histopathology 2006; 48: 223-32.
9. Klebe S, Nurminen M, Leigh J, et al. Diagnosis of epithelial mesothelioma using tree-based regression analysis and a minimal panel of antibodies. Pathology 2009; 41: 140-8.
10. Yan T, Boyer M, Tin M, et al. Extrapleural pneumonectomy for malignant pleural mesothelioma: Outcomes of treatment and prognostic factors. J Thorac Cardiovasc Surg 2009; 138: 619-24.
11. Travis WD, Brambilla E, Muller-Hermelink HK, et al. World Health Organization Classification of Tumours. Pathology and Genetics of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press, 2004.
12. Dejmek A, Hjerpe A. Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: stepwise logistic regression analysis. Cytopathology 2000; 11: 8-17. (Pubitemid 30106433)
13. Carella R, Deleonardi G, D'Errico A, et al. Immunohistochemical panels for differentiating epithelialmalignantmesotheliomafromlung adenocarcinoma: a study with logistic regression analysis. Am J Surg Pathol 2001; 25: 43-50. (Pubitemid 32001831)
14. Dejmek A, Hjerpe A. Immunohistochemical reactivity in mesothelioma and adenocarcinoma: A stepwise logistic regression analysis. APMIS 1994; 102: 255-64. (Pubitemid 24185955)
15. Bassarova A, Nesland J, Davidson B. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions. Am J Surg Pathol 2006; 30: 878-82. (Pubitemid 44264979)